Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients

Launched by ASSIUT UNIVERSITY · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain markers in the blood can help predict the outcome for patients who have experienced a specific type of heart attack called ST-elevation myocardial infarction (STEMI). The focus is on three markers: Galectin-3, soluble ST2, and B-type natriuretic peptide (BNP), which may provide valuable information about heart health and the risk of developing heart failure after a heart attack. The goal is to identify patients at higher risk so they can receive early treatment to prevent heart failure from developing.

To participate in this trial, individuals need to be at least 18 years old and have been hospitalized for their first STEMI treated with a specific procedure called percutaneous coronary intervention (pPCI). However, those with a history of heart issues, severe kidney or liver disease, or certain other health conditions will not be eligible. If you qualify, you’ll be monitored and tested to help researchers understand how these blood markers relate to heart health. The trial is not yet recruiting participants but aims to contribute important knowledge that could improve care for future heart attack patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years.
• • 2. Hospital admission due to first-time STEMI treated with pPCI.
• Exclusion Criteria:
• • History of previous acute coronary syndrome, Previously diagnosed HF or asymptomatic LV dysfunction with LVEF \<50% or previously diagnosed significant valvular disease or any other previously diagnosed structural heart disease Severe renal dysfunction, Severe liver disease, Chronic inflammatory disease, Current neoplastic disease